Telaglenastat (CB-839) is an investigational, first-in-class, selective, orally bioavailable, small molecule inhibitor of both splice variants (KGA and GAC) of glutaminase, currently under clinical investigation for the treatment of several cancers including RCC [28]. The gene discussed is GLS; the disease is renal cell carcinoma.